R. E. Glover

1.7k citations

45 papers · 853 indexed · 1 hit paper · h-index 13

Impact in

Applied Microbiology and Biotechnology top 1%
- Antibiotic Use and Resistance
Modeling and Simulation top 2%
- COVID-19 epidemiological studies

Papers in ⓘ

Applied Microbiology and Biotechnology 16
- Antibiotic Use and Resistance 16
Modeling and Simulation 4
- COVID-19 epidemiological studies 4

Co-authors: Gwenan M. Knight (4 shared papers)Clare Chandler (3 shared papers)Naomi M. Fuller (1 shared paper)Esther van Kleef (1 shared paper)Sam Willcocks (1 shared paper)Rumina Hasan (1 shared paper)Christopher Finn McQuaid (1 shared paper)Ioana D. Olaru (1 shared paper)
Journals: Journal of Clinical Epidemiology (4 papers)The Lancet Microbe (3 papers)BMJ (3 papers)European Journal of Public Health (2 papers)Antibiotics (2 papers)
Partner nations: United Kingdom United States Canada

In The Last Decade

R. E. Glover

37 papers receiving 824 citations

Hit Papers

align trajectories log scale

Antimicrobial resistance and COVID-19: Intersections and implications 2021 · 240 citations

Peers

Countries citing papers authored by R. E. Glover

Since Specialization

Citations

This map shows the geographic impact of R. E. Glover's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. E. Glover with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. E. Glover more than expected).

Fields of papers citing papers by R. E. Glover

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. E. Glover. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. E. Glover. The network helps show where R. E. Glover may publish in the future.

Co-authors

The 25 scholars most cited alongside R. E. Glover, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with R. E. Glover Line = papers co-authored together R. E. Glover links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 45 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Antimicrobial resistance and COVID-19: Intersections and implications eLife ·Gwenan M. Knight, R. E. Glover, Christopher Finn McQuaid, Ioana D. Olaru, Karin Gallandat, Quentin J. Leclerc, Naomi M. Fuller, Sam Willcocks, Rumina Hasan, Esther van Kleef, Clare Chandler Hit paper breakdown →	2021	240
2	A framework for identifying and mitigating the equity harms of COVID-19 policy interventions Journal of Clinical Epidemiology ·R. E. Glover, May CI van Schalkwyk, Elie A. Akl, Elizabeth Kristjannson, Tamara Lotfi, Jennifer Petkovic, Mark Petticrew, Kevin Pottie, Peter Tugwell, Vivian Welch	2020	121
3	Temporal Changes in Ebola Transmission in Sierra Leone and Implications for Control Requirements: a Real-time Modelling Study PLoS Currents ·Anton Camacho, Adam J. Kucharski, Yvonne Aki-Sawyerr, Mark A. White, Stefan Flasche, Marc Baguelin, Timothy M. Pollington, Julia Carney, R. E. Glover, Elizabeth Smout, Amanda Tiffany, W. John Edmunds, Sebastian Funk	2015	82
4	Measuring the impact of Ebola control measures in Sierra Leone Proceedings of the National Academy of Sciences ·Adam J. Kucharski, Anton Camacho, Stefan Flasche, R. E. Glover, W. John Edmunds, Sebastian Funk	2015	73
5	Parallel memory systems for talking about location and age in precuneus, caudate and Broca's region NeuroImage ·Mikkel Wallentin, Andreas Roepstorff, R. E. Glover, Neil Burgess	2006	60
6	Mathematical modelling for antibiotic resistance control policy: do we know enough? BMC Infectious Diseases ·Gwenan M. Knight, Nicholas G. Davies, Caroline Colijn, Francesc Coll, Tjibbe Donker, Danna R. Gifford, R. E. Glover, Mark Jit, Elizabeth J. Klemm, Sonja Lehtinen, Jodi A. Lindsay, Marc Lipsitch, Martin Llewelyn, Ana Mateus, Julie V. Robotham, Mike Sharland, Dov J. Stekel, Laith Yakob, Katherine E. Atkins	2019	48
7	Vaccinating against covid-19 in people who report allergies BMJ ·R. E. Glover, Robert Urquhart, Joanna Lukawska, Kimberly G. Blumenthal	2021	23
8	Methodological guidance for incorporating equity when informing rapid-policy and guideline development Journal of Clinical Epidemiology ·Omar Dewidar, Brenda Allen Kawala, Alba Antequera, Andrea C. Tricco, David Tovey, Sharon E. Straus, R. E. Glover, Janice Tufte, Olivia Magwood, Maureen Smith, Cheow Peng Ooi, Anna Dion, Mireille Goetghebeur, Ludovic Revéiz, Stefano Négrini, Peter Tugwell, Jennifer Petkovic, Vivian Welch	2022	19
9	Impact of a multiplex PCR point-of-care test for influenza A/B and respiratory syncytial virus on an acute pediatric hospital ward Diagnostic Microbiology and Infectious Disease ·Andrés I. Vecino-Ortiz, Simon Goldenberg, Sam Douthwaite, Chih‐Yuan Cheng, R. E. Glover, Catherine Mak, Elisabeth J Adams	2018	15
10	The antibiotic subscription model: fostering innovation or repackaging old drugs? The Lancet Microbe ·R. E. Glover, Andrew C. Singer, Adam P. Roberts, Claas Kirchhelle	2022	14
11	Enzootic Pneumonia in Calves Journal of Comparative Pathology and Therapeutics ·A.R. Jennings, R. E. Glover	1952	14
12	Resources supporting trustworthy, rapid and equitable evidence synthesis and guideline development: results from the COVID-19 evidence network to support decision-making (COVID-END) Journal of Clinical Epidemiology ·Michael McCaul, David Tovey, Taryn Young, Vivian Welch, Omar Dewidar, Mireille Goetghebeur, Tamara Kredo, Andrea C. Tricco, R. E. Glover, Janice Tufte, Amir Qaseem, Ludovic Reveiz, Rebecca L. Morgan, Per Olav Vandvik, Iván D. Flórez	2022	14
13	HUMAN INFECTION WITH THE VIRUS OF CONTAGIOUS PUSTULAR DERMATITIS The Lancet ·G. Lloyd, A. Macdonald, R. E. Glover	1951	14
14	The Commercial Determinants of Health and Evidence Synthesis (CODES): methodological guidance for systematic reviews and other evidence syntheses Systematic Reviews ·Mark Petticrew, R. E. Glover, Jimmy Volmink, Laurence Blanchard, Éadaoin Cott, Cécile Knai, Nason Maani, James Thomas, Alice Tompson, May CI van Schalkwyk, Vivian Welch	2023	12
15	Sankey diagrams can clarify ‘evidence attrition’: A systematic review and meta-analysis of the effectiveness of rapid diagnostic tests for antimicrobial resistance Journal of Clinical Epidemiology ·R. E. Glover, Mustafa Al‐Haboubi, Mark Petticrew, Elizabeth Eastmure, Sharon J. Peacock, Nicholas Mays	2021	11
16	Governing Integrated Health and Social Care: An Analysis of Experiences in Three European Countries International Journal of Integrated Care ·Josephine Exley, R. E. Glover, Martha McCarey, Sarah Orleans Reed, Anam Ahmed, Hubertus JM Vrijhoef, Tommaso Manacorda, Concetta M. Vaccaro, Francesco Longo, Ellen Stewart, Nicholas Mays, Ellen Nolte	2024	10
17	Antimicrobial resistance at the G7 BMJ ·R. E. Glover, Gwenan M. Knight, Clare Chandler	2021	9
18	How pharmaceutical and diagnostic stakeholders construct policy solutions to a public health ‘crisis’: an analysis of submissions to a United Kingdom House of Commons inquiry into antimicrobial resistance Critical Public Health ·R. E. Glover, Mark Petticrew, Nicholas Mays, Claire Thompson	2022	9
19	NIMble innovation—a networked model for public antibiotic trials The Lancet Microbe ·R. E. Glover, Andrew C. Singer, Adam P. Roberts, Claas Kirchhelle	2021	8
20	Field Trials with B.C.G. for the Immunisation of Calves Against Tuberculosis * British Veterinary Journal ·R. E. Glover, J. N. Ritchie	1953	8

About R. E. Glover

R. E. Glover is a scholar working on Applied Microbiology and Biotechnology, Modeling and Simulation, Molecular Medicine, Clinical Biochemistry and Organizational Behavior and Human Resource Management, having authored 45 papers that have together received 853 indexed citations. Recurring topics across this work include Antibiotic Use and Resistance (16 papers), Global Public Health Policies and Epidemiology (5 papers), Primary Care and Health Outcomes (5 papers), Bacterial Identification and Susceptibility Testing (5 papers), Antibiotic Resistance in Bacteria (4 papers), COVID-19 epidemiological studies (4 papers), Pharmaceutical industry and healthcare (3 papers) and Disaster Response and Management (3 papers). The work is most often cited by research in Applied Microbiology and Biotechnology (195 citations), Modeling and Simulation (165 citations), Molecular Medicine (127 citations), Infectious Diseases (220 citations) and Emergency Medical Services (59 citations). R. E. Glover has collaborated with scholars based in United Kingdom, United States and Canada. Frequent co-authors include Gwenan M. Knight, Clare Chandler, Naomi M. Fuller, Esther van Kleef, Sam Willcocks, Rumina Hasan, Christopher Finn McQuaid, Ioana D. Olaru, Karin Gallandat and Quentin J. Leclerc. Their work appears in journals such as Journal of Clinical Epidemiology, The Lancet Microbe, BMJ, European Journal of Public Health and Antibiotics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact